NCT07117474View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 24, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Subjects With Mild Hypertension
Interventions
DRUG

HRS-9563, placebo

A single subcutaneous injection of HRS-9563 injection or placebo was administered

Trial Locations (1)

314408

RECRUITING

Zhejiang Provincial People's Hospital, Hangzhou

All Listed Sponsors
lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY